Chantix, Zyban Safety Issues Put Focus On REMS Assessment Efforts

GlaxoSmithKline is writing a questionnaire to ascertain whether patients receiving the firm's smoking cessation drug Zyban understand the risk of potential neuropsychiatric side effects